GEFITINIB KRKA 250 mg, tablets film-coated 30 tablets
Active ingredients: GÉFITINIB
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- GEFITINIB KRKA 250 mg, comprimés pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquettes OPA : polyamide orienté aluminium PVC-Aluminium de 30 comprimés
- Marketing authorisation holder
- KRKA (SLOVENIE)
- Reimbursement according to BDPM
- 100%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Jan 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62649604CIP73015698CIP133400930156988Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| GÉFITINIBcomprimé | 250 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.